Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


"Lagging Indicators": Is There A "Drug Lag" Between U.S. And Europe?

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The "drug lag" is back. The term - biopharma industry shorthand for the belief that new drugs reach the market faster in other countries (especially in Europe) than they do the in U.S. - was a common refrain in the late 1980s and early 1990s, and the Prescription Drug User Fee Act of 1992 was intended in part to address the perception that U.S. consumers suffered while FDA reviews dragged on

You may also be interested in...

FDA Not More Conservative Than EU, Jenkins Says; Investors Not Convinced

Perceptions that FDA is more conservative in its approval standards than its European regulatory counterpart are misguided and largely overblown, Office of New Drugs Director John Jenkins said

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

September 2010 Approvals






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts